Medical XpressRanking High Blood Pressure Drug Combinations From Most to Least Tolerated

ℹ️ Observational Association Only Evidence

Treatment discontinuation within the first year affects an estimated 30-80% of patients newly prescribed antihypertensive therapy, frequently driven by side effects. This network meta-analysis is the first comprehensive tolerability comparison of antihypertensive drug classes and combinations in two decades, using SUCRA ranking to synthesize direct and indirect trial comparisons across 716 double-blind RCTs.

Clinical Considerations

• ARBs appeared in four of the five best-tolerated treatment options; ARB monotherapy had fewer treatment withdrawals than placebo across the pooled dataset
• ARB plus CCB ranked as the best-tolerated combination; regimens containing CCBs alone or beta-blocker/diuretic combinations were associated with higher discontinuation
• CCBs were the only drug class associated with more headaches than placebo, consistent with cerebral vasodilation as a proposed mechanism
• Trial durations ranged from 4 to 26 weeks, limiting conclusions about long-term tolerability across diverse clinical populations
• Network meta-analysis relies substantially on indirect comparisons; many drug combinations were never tested head-to-head in the same trial

Practice Applications

• Consider ARB-based regimens as a first-line tolerability-informed choice in patients with prior antihypertensive discontinuation due to side effects
• Recognize the ARB-CCB combination as the best-supported dual-therapy option for tolerability when combination therapy is indicated
• Interpret rankings as comparative signals rather than definitive hierarchy; individual comorbidities, contraindications, and guideline indications remain primary drivers of drug selection
• Monitor for validation in longer-duration and more diverse real-world populations before applying ranking data to protocol-level changes